Market Overview

How Incyte Just Became A Major M&A Target

How Incyte Just Became A Major M&A Target
Related INCY
Bank Of America Sees NewLink Genetics As 'Undervalued'
Jim Cramer Gives His Opinion On Tripadvisor And Incyte
Related GILD
How To Use Options During Earnings Season
These Were The Most Bought And Sold Stocks In September
Trump Likely To Sign Executive Order On Drug Pricing 'Any Day' (Investor's Business Daily)

Incyte Corporation (NASDAQ: INCY) shares are up more than 4.7 percent Thursday following three new analyst notes focusing on new data from Gilead Sciences, Inc. (NASDAQ: GILD)’s SIMPLIFY 1 and 2 Phase III studies on patients with myelofibrosis (MF).

Leerink analyst Michael Schmidt believes the results likely mean a dead end for Gilead.

“Results from both trials are disappointing, in our view making it highly unlikely that GILD would be able to obtain regulatory approval,” Schmidt explains.

However, Gilead’s loss may be Incyte’s gain.

“We view these results as a positive for INCY given Momelotinib is the only late-stage competitor in MF,” Goldman Sachs analyst Terence Flynn writes.

Schmidt takes things one step farther and believes Incyte is now a prime buyout target.

“Removal of uncertainty on the revenue outlook of INCY’s key product [Jakafi] combined with increasing prospects of a repatriation holiday should make the company more attractive from an M&A standpoint,” Schmidt says.

RBC Capital analyst Michael Yee agrees that a buyout is a likely scenario at this point.

Yee believes that Gilead could choose to “go after INCY if their IDO data works in lung cancer… and try to buy it for their oncology assets, leadership, and expertise as well as for Jakafi.”

Incyte shares are down 3.1 percent year-to-date.

Latest Ratings for INCY

Sep 2017RBC CapitalInitiates Coverage OnSector Perform
Sep 2017BMO CapitalMaintainsOutperform
Sep 2017Raymond JamesUpgradesMarket PerformOutperform

View More Analyst Ratings for INCY
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Rumors M&A Analyst Ratings General Best of Benzinga


Related Articles (GILD + INCY)

View Comments and Join the Discussion!

Partner Center